◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Golden Throat Holdings Group Company Limited (6896) Financial History

Name: Golden Throat Holdings Group Company Limited (6896) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-10

Golden Throat Holdings Group Company Limited (6896) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Liuzhou, China with about 840 employees. Its market capitalization is roughly CNY 2 billion. In the fiscal year ended 2025-12-31, 6896 reported CNY 943M in revenue and CNY 251M in net income.

Golden Throat Holdings Group Company Limited, an investment holding company, manufactures and sells pharmaceutical, healthcare food, and other products in the People's Republic of China and internationally.

Interactive charts & full statements →

6896 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CNY 943M	CNY 1.2B	CNY 961M	CNY 992M	—
Gross Profit	CNY 717M	CNY 894M	CNY 698M	CNY 721M	—
Operating Income (EBIT)	CNY 316M	CNY 429M	CNY 350M	CNY 368M	—
Net Income	CNY 251M	CNY 319M	CNY 250M	CNY 281M	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6896 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(CNY 339M)	(CNY 404M)	(CNY 243M)	(CNY 114M)	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6896 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 2.3B	CNY 2.3B	CNY 2.3B	CNY 2.3B	—
Total Liabilities	CNY 912M	CNY 785M	CNY 748M	CNY 760M	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6896 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

AMLX · Amylyx Pharmaceuticals, Inc. — $3 billion
2552 · Hua Medicine (Shanghai) Ltd. — $3 billion
BCRX · BioCryst Pharmaceuticals, Inc. — $2 billion
RGC · Regencell Bioscience Holdings Limited — $2 billion
PBH · Prestige Consumer Healthcare Inc. — $2 billion
2561 · VISEN Pharmaceuticals — $2 billion
BHC · Bausch Health Companies Inc. — $2 billion
2633 · Jacobson Pharma Corporation Limited — $2 billion

← 6894 All “0-9” companies 6897 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.